Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash from Financing Activities (2016 - 2025)

Celldex Therapeutics has reported Cash from Financing Activities over the past 16 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $1.3 million for Q4 2025, up 249.48% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (down 99.46% YoY), and the annual figure for FY2025 was $2.4 million, down 99.46%.
  • Cash from Financing Activities for Q4 2025 was $1.3 million at Celldex Therapeutics, up from $774000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for CLDX hit a ceiling of $436.1 million in Q1 2024 and a floor of -$25000.0 in Q2 2021.
  • Median Cash from Financing Activities over the past 5 years was $560000.0 (2021), compared with a mean of $46.9 million.
  • Biggest five-year swings in Cash from Financing Activities: crashed 100.02% in 2021 and later skyrocketed 62740.35% in 2024.
  • Celldex Therapeutics' Cash from Financing Activities stood at $426000.0 in 2021, then skyrocketed by 227.46% to $1.4 million in 2022, then soared by 15482.37% to $217.4 million in 2023, then crashed by 99.82% to $386000.0 in 2024, then skyrocketed by 249.48% to $1.3 million in 2025.
  • The last three reported values for Cash from Financing Activities were $1.3 million (Q4 2025), $774000.0 (Q3 2025), and $63000.0 (Q2 2025) per Business Quant data.